An opioid is a substance whose primary pharmacological action is mediated through the body's opioid receptors, producing analgesia, sedation, and at sufficient dose pronounced euphoria and respiratory depression. The class is defined by receptor activity rather than chemical scaffold or botanical origin — a functional grouping that spans naturally occurring plant alkaloids, semi-synthetic derivatives, and entirely laboratory-built compounds.
Membership covers a chemically diverse range. Plant-derived members include morphine and codeine from the opium poppy and the kratom alkaloids mitragynine and 7-hydroxymitragynine.
Semi-synthetics include heroin, oxycodone, hydromorphone, and buprenorphine; the fully synthetic branch spans methadone, the phenylpiperidines fentanyl and carfentanil, and recent novel synthetic opioids such as isotonitazene and brorphine. Despite their structural diversity, all converge on the same receptor system.[1]
Opioids are central to modern medicine for acute, post-surgical, and cancer pain, and several long-acting members are first-line treatments for opioid use disorder itself. They are also among the most widely used recreational and illicit drugs. Their subjective effects range from warmth and analgesia at low exposure, through pronounced sedation and cognitive slowing, to stupor and respiratory failure at the high end of the dose range.[2]
Pharmacology
Most opioids reach their characteristic effects by a single shared route: agonist binding to one or more of the three classical opioid receptors — mu (MOP), delta (DOP), and kappa (KOP) — which are Gi/Go-coupled G-protein-coupled receptors expressed throughout the pain pathway, brainstem, and limbic reward circuitry.[1]
Receptor activation triggers three converging inhibitory effects inside the cell: inhibition of adenylyl cyclase, suppression of voltage-gated calcium channels, and activation of inward-rectifying potassium channels. The net result is reduced neuronal excitability and reduced synaptic output in circuits where opioid receptors are expressed.[2]
| Mode of action | Representative members | How it reaches the shared endpoint |
|---|---|---|
| Full MOP agonism | morphine, heroin, fentanyl, oxycodone, methadone | Maximally activates mu receptors; full triad of analgesia, euphoria, and dose-dependent respiratory depression |
| Partial MOP agonism | buprenorphine, mitragynine, 7-hydroxymitragynine | Submaximal receptor activation even at saturating doses; ceiling effect attenuates but does not abolish respiratory risk |
| Mixed-mechanism MOP agonism | tramadol, tapentadol, tianeptine | Weaker direct MOP activity combined with monoaminergic or glutamatergic effects; opioid character emerges at higher exposures |
| High-affinity competitive antagonism | naloxone | Binds MOP without activating it; displaces agonists and reverses their effects |
The mechanistic detail matters less for safety than the shared endpoint: respiratory drive is brainstem-mediated and dose-dependently suppressed by mu activation in the preBötzinger complex and the Kölliker-Fuse nucleus, the pontomedullary nuclei that generate and regulate the breathing rhythm.[3]
Opioids hyperpolarize these neurons directly and suppress glutamatergic drive to them; at the same time they blunt the chemoreceptor reflexes that would normally detect rising CO2 and falling O2. Reduced respiratory drive and suppressed corrective reflexes together explain why opioid overdose can progress silently and rapidly.[3]
The euphoria that drives recreational use and reinforces dependence arises by the same disinhibition logic in the ventral tegmental area: mu agonism silences GABAergic interneurons that tonically inhibit dopamine projection neurons, producing a burst of dopamine release into the nucleus accumbens.[2]
Substances
The brief's twenty-nine members span every chemical origin within the class, from poppy isolates to novel benzimidazoles. A representative subset illustrates the range:
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| Morphine | Natural opiate | Pharmacological reference compound; the molecule against which clinical equianalgesic potency is expressed |
| Codeine | Natural opiate | Lower-potency MOP agonist whose effects depend largely on hepatic conversion to morphine |
| Heroin | Semi-synthetic | Diacetylated morphine derivative with rapid CNS penetration; the dominant illicit opioid for much of the modern era |
| Oxycodone | Semi-synthetic | Widely prescribed full MOP agonist central to the prescription-opioid mortality wave of the late 1990s and 2000s |
| Buprenorphine | Semi-synthetic partial agonist | High MOP affinity with a ceiling on respiratory depression; first-line maintenance agent for opioid use disorder |
| Methadone | Synthetic diphenylheptane | Long elimination half-life and additional NMDA antagonism; used for chronic pain and OUD maintenance |
| Fentanyl | Synthetic phenylpiperidine | High-potency lipophilic full agonist; the dominant driver of recent illicit-supply overdose mortality |
| Carfentanil | Synthetic phenylpiperidine | Extreme-potency fentanyl analogue associated with mass-casualty overdose clusters in the illicit supply |
| Tramadol | Atypical synthetic | Weak MOP agonist with monoamine reuptake inhibition; opioid character largely mediated by the metabolite O-desmethyltramadol |
| Kratom (mitragynine, 7-hydroxymitragynine) | Plant-derived atypical | Partial MOP agonism combined with adrenergic and serotonergic activity, giving a mixed stimulant/opioid profile[4] |
| Isotonitazene, brorphine, U-47700 | Novel synthetic opioid | Structurally unlike morphinan or phenylpiperidine scaffolds; confirmed full MOP agonists, with the nitazenes exceeding fentanyl in potency[5] |
| Naloxone | Competitive antagonist | The sole non-agonist member; reverses opioid-induced respiratory depression by displacing agonists from MOP |
These members differ widely in onset, duration, and absolute potency, but every agonist among them produces the same characteristic effect cluster — and every agonist among them is reversible, in principle, by naloxone.
Subjective Effects
Across the opioid class the subjective trajectory tracks one axis — deepening mu-receptor activation — as exposure rises. The onset curve and the ceiling differ by member and by route, but the phenomenological sequence is stable.[2]
| Exposure | Characteristic effects |
|---|---|
| Low | Analgesia covering both pain intensity and the affective suffering of pain; diffuse warmth, contentment, and anxiolysis; mild sedation; characteristic pupillary constriction (miosis); reduced peristalsis; pruritus, particularly with intravenous routes |
| Moderate–high | Deepening sedation and cognitive clouding; nausea and vomiting via the chemoreceptor trigger zone; slowed respiratory rate; pronounced euphoria with rapid-onset routes (intravenous, smoked, insufflated) |
| High | Somnolence progressing to stupor and coma; shallow, slow, and ultimately arrested respiration; the classical overdose triad of miosis, unconsciousness, and respiratory depression |
Because the same mu-receptor activation drives both the sought-after analgesia and euphoria and the suppression of brainstem breathing, the margin between heavy sedation and life-threatening respiratory failure narrows as exposure rises — and narrows much faster with the high-potency synthetic members. Tolerance to analgesia, euphoria, and respiratory depression develops at roughly similar rates with chronic dosing, while miosis and constipation persist throughout long-term use.[6]
Safety
Risk profile
The defining acute danger of the opioid class is fatal respiratory depression. The same mu-receptor activation that produces analgesia and euphoria suppresses the brainstem circuits that drive breathing, and at sufficient dose can stop respiration entirely. In the United States, approximately 79,358 of the 105,007 drug overdose deaths recorded in 2023 involved opioids — more than three-quarters of the total.[7]
The modern overdose crisis has unfolded in three overlapping waves: prescription-opioid mortality rising from the late 1990s, a heroin-driven phase from around 2010, and from 2013 onward a phase dominated by illicitly manufactured fentanyl and its analogues.[8] Cumulatively, approximately 806,000 people in the US died of opioid overdose between 1999 and 2023.[8]
Combining an opioid with any other CNS depressant sharply raises the risk of fatal respiratory depression. Benzodiazepines and alcohol act at non-opioid targets but converge on brainstem respiratory suppression, and their effects stack with those of an opioid.
Cohort data summarized by NIDA found that people prescribed an opioid and a benzodiazepine concurrently had overdose death rates approximately ten times those of people prescribed an opioid alone; about 14% of US opioid overdose deaths in 2021 involved a benzodiazepine.[9]
The high-potency synthetic members — fentanyl, carfentanil, acetylfentanyl, and the nitazenes isotonitazene and brorphine — require far smaller absolute quantities to produce respiratory arrest than morphine-equivalent natural or semi-synthetic opioids. They routinely appear in the illicit supply as adulterants in counterfeit pills, heroin, and other preparations, and standard immunoassay toxicology screens detect many of them unreliably.[5]
Naloxone reverses opioid-induced respiratory depression by displacing agonists from the mu receptor. Its duration of action is shorter than that of many opioids, so renewed depression after initial reversal is possible, and reversal of high-potency or long-acting opioids may require repeated dosing. Naloxone does not reverse the depressant effects of co-ingested alcohol or benzodiazepines.
Tolerance & dependence
Regular full-agonist use produces tolerance within days to weeks of continuous exposure, through receptor desensitization and internalization and through compensatory upregulation of downstream cAMP signaling.[6] Cross-tolerance between class members is well established but incomplete and asymmetric, which underpins the clinical practice of opioid rotation in chronic pain management.[6]
Physical dependence is an almost universal consequence of sustained opioid exposure and reflects neuroadaptation in noradrenergic and opioid-receptor circuitry. When opioid input is abruptly removed, the adapted circuits rebound: the withdrawal syndrome includes dysphoria, anxiety, craving, insomnia, nausea, vomiting, diarrhoea, muscle aches, yawning, lacrimation, rhinorrhoea, sweating, piloerection, and autonomic instability.[10] Onset is within hours for short-acting agents such as heroin and oxycodone, and is delayed and more prolonged for long-acting methadone.[10]
Opioid withdrawal is intensely aversive but not inherently life-threatening in otherwise healthy adults — a meaningful contrast with alcohol and benzodiazepine withdrawal, which can kill. The lethal hazard in opioid cessation lies elsewhere: tolerance falls rapidly during even a brief period of abstinence, and returning to a previously tolerated dose can now produce fatal respiratory depression. This is the mechanism behind the high overdose mortality seen in the days and weeks after detoxification, incarceration, or hospitalization.
Recovery
Opioid use disorder is one of the most clinically tractable forms of substance dependence: the pharmacology of recovery is well understood and effective medications exist.
If you or someone you know is dependent on an opioid, a clinician or an opioid-treatment programme can structure a safe path: medically supervised withdrawal management, followed by maintenance pharmacotherapy and behavioural support. Carrying naloxone, and not using alone, sharply reduces the chance that an overdose becomes a fatal one.
Recovery resources, crisis lines, and support pathways → View all
Members
references
- [1] ^abPathan, H. and Williams, J. (2012) Basic opioid pharmacology: an update — British Journal of Pain doi:10.1177/2049463712438493
- [2] ^abcdAl-Hasani, R. and Bruchas, M.R. (2011) Molecular mechanisms of opioid receptor-dependent signaling and behavior — Anesthesiology doi:10.1097/aln.0b013e318238bba6
- [3] ^abBateman, J.T. and Saunders, S.E. and Levitt, E.S. (2023) Understanding and countering opioid-induced respiratory depression — British Journal of Pharmacology doi:10.1111/bph.15580
- [4] ^Kruegel AC, Uprety R, Grinnell SG, Langreck C, Pekarskaya EA, et al. (2019) 7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects — ACS Central Science doi:10.1021/acscentsci.9b00141
- [5] ^abVandeputte MM, Tsai MM, Chen L, Glatfelter GC, Walther D, Stove CP, Shi L, Baumann MH (2023) Comparative neuropharmacology of structurally distinct non-fentanyl opioids appearing on recreational drug markets worldwide. — Drug and Alcohol Dependence doi:10.1016/j.drugalcdep.2023.109939
- [6] ^abcAdriaensen, H. and Vissers, K. and Noorduin, H. and Meert, T. (2003) Opioid tolerance and dependence: an inevitable consequence of chronic treatment? — Acta Anaesthesiologica Belgica PMID:12703345